Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 18/20 | 1.00 |
| ▸ | NPC1 | O15118 | 17/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.81 |
| ▸ | MEN1 | O00255 | 5/20 | 0.81 |
| ▸ | GAA | P10253 | 2/20 | 0.81 |
| ▸ | EEF2K | O00418 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 10/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 4/20 | 0.59 |
| ▸ | USP2 | O75604 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431495 | 0.99 | RAB9A (0.98) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL432067 | 0.90 | NPC1 (1.00) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL427378 | 0.87 | NPC1 (0.95) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL19769212 | 0.80 | RAB9A (0.97) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL14954806 | 0.80 | NPC1 (0.78) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL12562439 | 0.78 | NPC1 (0.76) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL29858907 | 0.78 | NPC1 (1.00) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL14955121 | 0.78 | NPC1 (0.81) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL425467 | 0.78 | NPC1 (1.00) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL13954997 | 0.77 | RAB9A (1.00) | RAB9ANPC1PKMSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2014089378-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | RAB9A 1654/4885NPC1 2091/4885PKM 1423/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | RAB9A 1518/4885NPC1 1976/4885PKM 1450/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | RAB9A 1518/4885NPC1 1976/4885PKM 1450/4885 |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | RAB9A 1654/4885NPC1 2091/4885PKM 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.